[Molecular cytogenetic characterization of five patients with myeloid leukemia and t(12;22)(p13;q12)].

H. Shao,Qian Yang,Y. Gong,S. Bai,Jun Zhang,Yong Wang,Juan Shen,Chun-xiao Wu,H. Qiu,Suning Chen,Jinlan Pan
DOI: https://doi.org/10.3760/cma.j.issn.1003-9406.2019.02.004
2019-02-10
Abstract:OBJECTIVE To explore the clinical and laboratory characteristics of 5 patients with myeloid leukemia and t(12;22)(p13;q12). METHODS Bone marrow cells were cultured for 24 h and analyzed by standard R-banding. Rearrangement of the MN1 gene was detected by fluorescence in situ hybridization (FISH) using dual color break-apart MN1 probes. MN1-ETV6 and ETV6-MN1 fusion genes were detected by reverse transcription polymerase chain reaction (RT-PCR). And the products were subjected to direct sequencing. RESULTS Among the 5 patients, 2 had AML-M0, 2 had AML-M4, and 1 had CMM0L at the initial diagnosis. t(12;22)(p13;q12) was the primary abnormality among all patients. Rearrangements of MN1 gene were detected by FISH in all patients. MN1-ETV6 and ETV6-MN1 fusion genes were detected respectively in 4 and 3 patients. CONCLUSION t(12;22)(p13;q12) is a rare but recurrent chromosomal abnormality in myeloid leukemia, and is related to poor prognosis. allo-SCT is valuable for patients with t(12;22)(p13;q12).
Medicine
What problem does this paper attempt to address?